Key Takeaways

•  Expanding access: $30M raised to expand coverage and enter new markets

•  Proven outcomes: 97% of graduates experience overall clinical improvement, 99%+ remain out of the hospital one year post-discharge — measurable ROI for payors

•  Strong growth: 2x revenue in 2025, 2x expected in 2026 — while delivering consistent, high-quality care

InStride, the most trusted, insurance-covered specialty program for young people living with complex anxiety, OCD, and related disorders, raised a $30M Series C from new strategic investors Echo Health Ventures and FMZ Ventures, with continued participation from existing backers: .406 Ventures, Valtruis, General Catalyst, and Mass General Brigham Ventures. The capital will fuel InStride’s expansion into new markets while deepening access in existing ones, ensuring more families can get the high-quality specialty care they need. InStride continues to demonstrate strong financial performance while sustaining the clinical quality that defines its model.

“We set out to prove that the highest-quality specialty care could also be the most scalable — and the data shows that’s exactly what we’ve built. This capital lets us go deeper in existing markets and broader into new ones, and Echo Health Ventures and FMZ Ventures are ideal partners for this next chapter alongside our existing investors. Clinical quality has always been at the center of everything we do, and that remains our true north.“— John Voith, Co-Founder and CEO, InStride

The Most Trusted Program

Built on evidence-based care and expertise from the nation’s leading psychiatric hospital, our program pairs every young person with a family-centered team—including a psychiatrist, therapist, and exposure coach. Working alongside caregivers, schools, and pediatricians, these clinicians are supported by domain-specific AI designed to reinforce best practices, reduce variation, and scale consistent, high-quality care—while keeping clinical decision-making and relationships firmly in human hands.

Today, InStride operates in 17 states and has served 5,000+ patients, with national expansion underway. We believe trust must be earned, and families consistently tell us we have earned it. In our most recent patient experience data, 96% of patients and 98% of caregivers reported they would recommend InStride to a friend.

That trust is matched by strong clinical results. In our most recent outcomes data from May 2026, 97% of InStride graduates experienced overall clinical improvement, and 81% of caregivers reported a reduction in their own strain. These results also translate into fewer crises and less need for escalation to higher levels of care. More than 90% of caregivers reported a reduction in missed work and neglected duties from intake to graduation, creating measurable value for both families and employers.

The impact persists well beyond treatment. Across a cohort of patients surveyed one year after discharge, 99%+ remain out of the hospital in the following 12 months.

We are proud of these results because they reflect what InStride was built to do: combine clinical expertise, family-centered care, and purpose-built technology to remove the barriers and burdens of traditional mental healthcare, reduce the need for higher-acuity interventions, and help young people and families get better in the setting where they live their lives.

New and Returning Investors

Echo Health Ventures and FMZ Ventures join this round as new strategic investors, and their involvement extends well beyond financial support. Echo Health Ventures’ limited partners include Blue Cross Blue Shield plans across the country — a bridge to making InStride accessible to everyone who needs it. As Kurt Sheline, Partner at Echo Health Ventures, noted: “As behavioral health pivots from access to outcomes, we believe high-quality specialty models like InStride are incredibly well-positioned. They’ve built the wraparound care and incentive alignment that consistently delivers durable ROI to payors, and have proven their ability to replicate the model across numerous markets at scale. We are excited to support the company in its next phase of growth.” Michael Zeisser, Founder and Managing Partner at FMZ Ventures, added: “Few experiences matter more than helping a child regain confidence and resilience. InStride Health is delivering that transformation for families at scale.” And the return of all existing investors further demonstrates their belief in InStride’s continued ability to scale its proven care model.

What’s Next

The Series C funds expansion into new markets — adding net new specialty capacity for payors and employers where evidence-based care for complex anxiety and OCD is nearly impossible to find. It also deepens coverage in existing markets, ensuring that geography and insurance status are no longer barriers to evidence-based care. What that really means is more young people graduating from care, regaining their passions, and thriving. Clinical quality is our north star. It’s what our families depend on, how our payor partners measure us, and what this investment is designed to protect as we scale.